

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Ryckmans Thomas :

APPLICATION NO.: 10/588,878 : Examiner: Unknown

FILING DATE: 08/09/2006 : Group Art Unit: Unknown

TITLE: Compounds Useful In Therapy :

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO/SB/08A which lists the references cited by the applicant(s).

1. US 4 481 360 A 11/02/84
2. US 7 084 164 08/01/06
3. WO 01/58880 A 08/16/01
4. EP 1 293 503 A 03/19/03
5. WO 01/87855 A 11/22/01
6. KAKEFUDA, AKIO ET AL: "Discovery of 4,5-Diphenyl-1,2,4-triazole Derivatives as a Novel Class of Selective Antagonists for the Human VIA Receptor" BIOORGANIC & MEDICINAL CHEMISTRY , 10(6), 1905-1912 CODEN: BMECEP; ISSN: 0968-0896, 2002, XP002281248
7. KAKEFUDA A ET AL: "Synthesis and pharmacological evaluation of 5-(4-bi phenyl)-3-methyl-4 phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressinVIA receptor" JOURNAL OF MEDICINAL AND PHARMACEUTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY EASTON, US, vol. 45, no. 12, 2002, pages 2589-2598, XP002237488

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). The listing of the references on the PTO/SB/08A form is not intended to represent or imply that these references are prior art to the

Patent Application
Attorney Docket No. PC26077A

above-captioned application. Applicants reserve the right to challenge the status of any reference so listed or otherwise identified as prior art.

It is requested that the references listed on the attached form PTO/SB/08A be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445, including all fees required under 37 C.F.R. 1.97.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: September 20 2006

/Andrea Dorigo/
Andrea E. Dorigo, Reg. No. 47,532
Attorney for Applicant(s)

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 733-1898

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Known	
(use as many sheets as necessary)		Application Number	10/588,878
		Filing Date	08/08/06
		First Named Inventor	Ryckmans Thomas
		Art Unit	Unknown
		Examiner Name	Unknown
		Attorney Docket Number	PC26077A
Sheet	1	of	1

U.S. PATENT DOCUMENTS				
EXAMINER INITIAL*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number Kind Code ² (if known)		
		US 4 481 360 A	11/02/84	
		US 7 084 164	08/01/06	

FOREIGN PATENT DOCUMENTS				
EXAMINER INITIAL	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Country Code ³ Number Kind Code ⁴ (if known)		
		WO 01/55880 A	06/16/01	
		EP 1 283 603 A	03/19/03	
		WO 01/67255 A	11/22/01	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initial	Cite No. ¹	T ²		
	KAKEFUDA, AKIO ET AL: "Discovery of 4,5-Diphenyl-1,2,4-Triazole Derivatives as a Novel Class of Selective Antagonists for the Human V1A Receptor" BIOCORGANIC & MEDICINAL CHEMISTRY , 10(6), 1905-1912 CODEN: BMCECP, ISSN: 0968-0898, 2002, XP002261246			
	KAKEFUDA A ET AL: "Synthesis and pharmacological evaluation of 5-(4-(1 phenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives: a novel class of selective antagonists for the human vasopressin/V1A receptor" JOURNAL OF MEDICINAL AND PHARMACEUTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY EASTON, US, vol. 45, no. 12, 2002, pages 2589-2598, XP002237488			

EXAMINER	DATE CONSIDERED
----------	-----------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Application unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 201.04

² Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Application unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 201.04

³ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Application unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 201.04

⁴ Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Application unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 201.04